New Approaches for Anemia in MDS
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 Suppl 1 |
|---|---|
| Enthalten in: |
Clinical lymphoma, myeloma & leukemia - 20 Suppl 1(2020) vom: 15. Sept., Seite S59-S60 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Platzbecker, Uwe [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.12.2021 Date Revised 11.01.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/S2152-2650(20)30463-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314359974 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314359974 | ||
| 003 | DE-627 | ||
| 005 | 20231225152547.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2152-2650(20)30463-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM314359974 | ||
| 035 | |a (NLM)32862871 | ||
| 035 | |a (PII)S2152-2650(20)30463-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Platzbecker, Uwe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New Approaches for Anemia in MDS |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2021 | ||
| 500 | |a Date Revised 11.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Myelodysplastic syndromes | |
| 650 | 4 | |a emerging therapies | |
| 650 | 4 | |a erythroid line | |
| 650 | 4 | |a lower-risk disease | |
| 650 | 7 | |a Immunoglobulin Fc Fragments |2 NLM | |
| 650 | 7 | |a Isoquinolines |2 NLM | |
| 650 | 7 | |a Oligonucleotides |2 NLM | |
| 650 | 7 | |a Recombinant Fusion Proteins |2 NLM | |
| 650 | 7 | |a luspatercept |2 NLM | |
| 650 | 7 | |a AQK7UBA1LS |2 NLM | |
| 650 | 7 | |a Activin Receptors, Type II |2 NLM | |
| 650 | 7 | |a EC 2.7.11.30 |2 NLM | |
| 650 | 7 | |a imetelstat |2 NLM | |
| 650 | 7 | |a F60NE4XB53 |2 NLM | |
| 650 | 7 | |a Glycine |2 NLM | |
| 650 | 7 | |a TE7660XO1C |2 NLM | |
| 650 | 7 | |a roxadustat |2 NLM | |
| 650 | 7 | |a X3O30D9YMX |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical lymphoma, myeloma & leukemia |d 2010 |g 20 Suppl 1(2020) vom: 15. Sept., Seite S59-S60 |w (DE-627)NLM195738748 |x 2152-2669 |7 nnns |
| 773 | 1 | 8 | |g volume:20 Suppl 1 |g year:2020 |g day:15 |g month:09 |g pages:S59-S60 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S2152-2650(20)30463-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 Suppl 1 |j 2020 |b 15 |c 09 |h S59-S60 | ||